Check out your Company Bowl for anonymous work chats.
To recognize World Cancer Day, FORMA employees wrote messages of inspiration in a journal that will be given to the children of the Jimmy Fund/Dana Farber Boston Children's Hospital Pediatric Blood Disorders and Cancer Center for patients to keep and read. We also wore lavender ribbons (which represent all cancer) to show that we are all in this fight together, and hope that one day, on February 4th, we can all wear ribbons in celebration of a cure.
It's a new year and a new FORMA! The team came together to focus on our 2020 corporate goals, as well as refresh our vision and values. There was plenty of energy in the room, partly due to these new mugs (which hold a LOT of coffee).
FORMA compounds continue to advance in our own pipeline and also in licensees' pipelines. Check out today's press release about progress that FORMA-grown molecules are making in the pipelines of Boehringer-Ingelheim and Celgene, now Bristol-Myers Squibb.
Today we announced clinical data for sickle cell disease candidate FT-4202 from #ASH19, demonstrating that multi-modal activity of PKR activation increases oxygen affinity and decreases sickle hemoglobin polymerization. http://glassdoor.com/slink.htm?key=vM2V9
Our LDO team had a blast playing laser tag! You didn't know the "L" in "LDO" stands for "Laser" did you? (Disclaimer: it doesn't. It stands for "Lead". As in "Lead Discovery and Optimization". But on occasion, it stands for "Laser".)
Promising Phase 1b/2 results from our olutasidenib program were announced today at #SNO2019. The data indicate the drug has blood-brain barrier penetration, and a number of patients with IDH1-mutated glioma have achieved stable disease at 4 months. We are hopeful that olutasidenib can transform the lives of patients in need. http://glassdoor.com/slink.htm?key=vMLAw
We look forward to attending the 2019 Society for NeuroOncology (SNO) Annual Meeting in Phoenix, AZ. We will be conducting an oral presentation on Wednesday at 9:45am and an E-Talk presentation on Saturday at 5:20pm on our Phase 1b/2 study of Olutasidenib (FT-2102), our next-gen IDH1m inhibitor. http://glassdoor.com/slink.htm?key=vMLAj
FORMA employees love giving back! All of this food was donated by the caring folks at FORMA Therapeutics, Inc. as part of our building's annual fundraiser. The donations will help needy families have a happy Thanksgiving! #formafuturewithforma #formafuture #formatherapeutics #fooddrive #thanksgiving
Today through Monday, Nov 11th, we’re excited to present new data for FT-4101, our novel FASN inhibitor in clinical development for the treatment of NASH, at the 2019 AASLD Liver Meeting in Boston, MA. Stop by and see us! If you can’t make it, you can read more about the data here: http://glassdoor.com/slink.htm?key=vMuCg
On Fridays everyone takes a turn providing breakfast! This morning at FORMA we had chicken and waffles, grits and gravy, eggs and bacon, and plenty of fruit. Comfort food on a cold day courtesy of our CEO who decided to share some of his favorites with the team! #formafuture #formafuturewithforma #fridaybreakfast #chickenandwaffles #comfortfood #formatherapeutics #formaculture
